Abstract
As the GIT Market begins to feature increasingly high levels of generic competition, the focus of pharmaceutical R&D strategies has shifted towards new therapy areas such as Crohn' s disease and Irritable Bowel Syndrome (IBS). Although such shifts are becoming the driving force for market transformation, growth rates may remain low due to the increased availability of effective generic medicines and fewer launches of innovative new drugs. ' The Gastrointestinal Market Outlook to 2012' is a new report published by Business Insights that provides a detailed epidemiological analysis of key indications within major GIT markets, and examines the factors impacting their prevalence. The dynamics of the market are examined through an analysis of leading brands within each indication and a profile of the pharma companies and market trends influencing the sales of GIT treatments. Forecasts for major product sales over the 2006-12 period are also provided.
Table of Contents
Executive Summary
- Patient potential of GIT therapeutic area
- Global market analysis
- Pipeline analysis
- Competitive landscape
Chapter 1 Patient potential of GIT
- therapeutic area
- Summary
- Introduction
- Gastroesophageal reflux disorder
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Peptic ulcer disease
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Irritable bowel syndrome
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Ulcerative colitis
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
- Crohn' s disease
- Overview
- Diagnosis, treatment and management
- Epidemiology
- Forecast epidemiology
Chapter 2 Global market analysis
- Summary
- Introduction
- Market analysis by country
- Licensing trends
- Market analysis by drug class
- Leading brand dynamics
- Key events in the GIT market
- Gastroesophageal reflux disorder and peptic ulcer disease
- Leading brands of the GERD/PUD market
- Proton pump inhibitor market analysis
- Market dynamics
- Key brands analysis
- Histamine-2 receptor antagonist market analysis
- Market dynamics
- Key brands analysis
- GERD/PUD sales forecasts to 2012
- Irritable bowel syndrome
- Competitive dynamics of IBS subclasses
- Leading brands of the IBS market
- GI sensorimotor modulators market analysis
- Market dynamics
- Key brands analysis
- Antispasmodics/anticholinergics
- Market dynamics
- IBS sales forecasts to 2012
- Inflammatory bowel disease: Crohn' s disease and ulcerative colitis
- Competitive dynamics of Crohn' s disease and ulcerative colitis subclasses
- Leading brands of IBD subclasses
- Immunosuppressants market analysis
- Market dynamics
- Key brands analysis
- Anti-rheumatic agents
- Market dynamics
- Key brands analysis
- Intestinal anti-inflammatory agents
- Market dynamics
- Key brands analysis
- IBD sales forecasts to 2012
- Total GIT sales forecasts to 2012
Chapter 3 Pipeline analysis
- Summary
- Introduction
- Key trends in R&D
- Increasing penetration of generics in the GERD/PUD market will continue to
- limit R&D investment
- Continuing, yet uncertain focus on drug development in irritable bowel
- syndrome
- Emerging therapies for the management of inflammatory bowel disease
- New mechanism of action
- The GIT therapeutic area pipeline
- Leading drugs in development
- Profiles of key pipeline products
- Phase II compounds
- tetomilast (OPC-6535)
- Alicaforsen (ISIS 2302)
- OX-17
- S-tenatoprazole-Na
- Phase III compounds
- Renzapride
- Kremezin (AST-120)
- Cimzia (certolizumab pegol)
- TAK-390MR (dexlansoprazole)
- Orencia (abatacept)
- Drugs in registration
- Ramosetron
- Recently marketed drugs
- Amitiza (lubiprostone)
- Pipeline forecasts
- Factors affecting forecasts
- GIT pipeline forecasts
Chapter 4 Competitive landscape
- Summary
- Introduction
- Market share
- AstraZeneca
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline
- Strategic analysis
- Sales and promotions
- Growth drivers
- Growth constraints
- Wyeth
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline
- Strategic analysis
- Sales and promotions
- Growth drivers
- Growth constraints
- Abbott
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline
- Strategic analysis
- Sales and promotions
- Growth drivers
- Growth constraints
- Johnson & Johnson
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline
- Strategic analysis
- Sales and promotions
- Growth drivers
- Growth constraints
- Takeda
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline
- Strategic analysis
- Sales and promotions
- Growth drivers
- Growth constraints
- Novartis
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline
- Strategic analysis
- Sales and promotions
- Growth drivers
- Growth constraints
- Astellas
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline
- Strategic analysis
- Sales and promotions
- Growth drivers
- Growth constraints
- Eisai
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline
- Strategic analysis
- Sales and promotions
- Growth drivers
- Growth constraints
- Altana
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline
- Strategic analysis
- Sales and promotions
- Growth drivers
- Growth constraints
- Procter & Gamble
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline
- Strategic analysis
- Sales and promotions
- Growth drivers
- Growth constraints
Chapter 5 Appendix
- IMS data
- Licensing status
- Index
- Index
List of Figures
- Figure 2.1: Global GIT market share by geography, 2006
- Figure 2.2: Licensing status of global GIT sales, 2005-06 ($bn)
- Figure 2.3: Competitive dynamics of the global GIT market by drug class, 2006
- Figure 2.4: Competitive dynamics of the leading 10 brands in the global GIT market, 2005-06
- Figure 2.5: Competitive dynamics of the global GERD/PUD market, 2005-06
- Figure 2.6: Competitive dynamics of the leading 10 brands in the global GERD/PUD market, 2005-06
- Figure 2.7: Competitive dynamics of the global IBS market, 2005-06
- Figure 2.8: Competitive dynamics of the leading 10 brands in the global IBS market, 2005-06
- Figure 2.9: Competitive dynamics of the global IBD market, 2005-06
- Figure 2.10: Competitive dynamics of the leading 10 brands in the global IBD market, 2005-06
- Figure 3.11: Prevailing R&D approaches
- Figure 3.12: The GIT pipeline by indication and stage of development, 2006
- Figure 3.13: Recently launched products and late-stage R&D compounds indicated for the GIT therapeutic area, 2006
- Figure 4.14: Competitive dynamics of the leading players in the global GIT market, 2006
- Figure 4.15: AstraZeneca' s GIT sales, 2006 ($m)
- Figure 4.16: Wyeth' s GIT sales, 2006 ($m)
- Figure 4.17: Abbott' s GIT sales, 2006 ($m)
- Figure 4.18: J&J' s GIT sales, 2006 ($m)
- Figure 4.19: Takeda' s GIT sales, 2006 ($m)
- Figure 4.20: Novartis' GIT sales, 2006 ($m)
- Figure 4.21: Astellas' GIT sales, 2006 ($m)
- Figure 4.22: Eisai' s GIT sales, 2006 ($m)
- Figure 4.23: Altana' s GIT sales, 2006 ($m)
- Figure 4.24: P&G' s GIT sales, 2006 ($m)
List of Tables
- Table 1.1: Estimated prevalence of major GIT indications in the seven major pharmaceutical markets, 2005
- Table 1.2: Estimated prevalence of GERD across the seven major markets, 2006
- Table 1.3: Forecast epidemiology of GERD across the seven major markets, 2006-12
- Table 1.4: Estimated prevalence of PUD in the seven major pharmaceutical markets, 2006
- Table 1.5: Forecast epidemiology of PUD across the seven major markets, 2006-12
- Table 1.6: Estimated prevalence of IBS in the seven major pharmaceutical markets, 2006
- Table 1.7: Forecast epidemiology of IBS across the seven major markets, 2006-12
- Table 1.8: Estimated prevalence of ulcerative colitis in the seven major pharmaceutical markets, 2006
- Table 1.9: Estimated epidemiology of UC across the seven major markets, 2006-12
- Table 1.10: Estimated prevalence of Crohn' s disease in the seven major pharmaceutical markets, 2006
- Table 1.11: Forecast prevalence of Crohn' s disease across the seven major markets, 2006-12
- Table 2.12: Market size ($m) and growth (%) of drug classes within the global GIT market, 2002-06
- Table 2.13: Market size ($m) and growth (%) of leading brands in the global GIT market, 2005-06
- Table 2.14: Market size ($m) and growth (%) of drug classes within the global GERD and PUD market, 2002-06
- Table 2.15: Market size ($m) and growth (%) of leading GERD/PUD products, 2005-06
- Table 2.16: GERD/PUD sales forecast, 2006-12 ($m)
- Table 2.17: Market size (US$) and growth (%) of drug classes within the global IBS market, 2002-06
- Table 2.18: Market size ($m) and growth (%) of leading IBS brands, 2005-06
- Table 2.19: IBS sales forecast, 2006-12 ($m)
- Table 2.20: Market Share ($m) and growth (%) of drug classes within the global IBD market, 2002-06
- Table 2.21: Market size ($m) and growth (%) of leading IBD brands, 2005-06
- Table 2.22: IBD sales forecast, 2006-12 ($m)
- Table 2.23: GIT therapeutic sales forecasts by drug class, 2006-12 ($m)
- Table 3.24: GIT pipeline sales forecasts, 2006-12 ($m)
- Table 4.25: Market share ($m) and growth (%) of leading corporations in the global GIT market, 2005-06
- Table 4.26: AstraZeneca' s GIT portfolio sales, 2005-06 ($m)
- Table 4.27: AstraZeneca' s R&D product pipeline, 2006
- Table 4.28: Promotional spend on major GIT drugs by AstraZeneca, 2005-06 ($m)
- Table 4.29: Wyeth' s GIT portfolio sales, 2005-06 ($m)
- Table 4.30: Wyeth' s R&D product pipeline, 2006
- Table 4.31: Promotional spend on major GIT drugs by Wyeth, 2005-06 ($m)
- Table 4.32: Abbott' s GIT portfolio sales, 2005-06 ($m)
- Table 4.33: Abbott' s R&D product pipeline, 2006
- Table 4.34: Promotional spend on major GIT drugs by Abbott, 2005-06 ($m)
- Table 4.35: J&J' s GIT portfolio sales, 2005-06 ($m)
- Table 4.36: J&J' s R&D product pipeline, 2006
- Table 4.37: Promotional spend on major drugs by J&J, 2005-06 ($m)
- Table 4.38: Takeda' s GIT portfolio sales, 2005-06 ($m)
- Table 4.39: Takeda' s R&D product pipeline, 2006
- Table 4.40: Promotional spend on major drugs by Takeda, 2005-06
- Table 4.41: Novartis' GIT portfolio sales, 2005-06 ($m)
- Table 4.42: Novartis' R&D product pipeline, 2006
- Table 4.43: Promotional spend on major drugs by Novartis, 2005-06 ($m)
- Table 4.44: Astellas' GIT portfolio sales, 2005-06 ($m)
- Table 4.45: Astellas' R&D product pipeline, 2006
- Table 4.46: Promotional spend on major drugs by Astellas, 2005-06
- Table 4.47: Eisai' s GIT portfolio sales, 2005-06 ($m)
- Table 4.48: Eisai' s R&D product pipeline, 2006
- Table 4.49: Promotional spend on major drugs by Eisai, 2005-06
- Table 4.50: Altana' s GIT portfolio sales, 2005-06 ($m)
- Table 4.51: Promotional spend on major drugs by Altana, 2005-06
- Table 4.52: P&G' s GIT portfolio sales, 2005-06 ($m)
- Table 4.53: P&G' s R&D product pipeline, 2006
